Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bavarian Nordic AS

www.bavarian-nordic.com

Latest From Bavarian Nordic AS

Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies

Lilly is targeting mRNA-based next-generation immunotherapies in its collaboration with Germany's CureVac, which could be worth more than $1.7bn for the family-office backed biotech.

Deals ImmunoOncology

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine

The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Bavarian Nordic Research Institute AS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Bavarian Nordic AS
  • Senior Management
  • Paul Chaplin, Pres. & CEO
    Ole Larsen, EVP, CFO
    Tommi Kainu, MD, PhD, EVP, CBO
  • Contact Info
  • Bavarian Nordic AS
    Phone: (45) 33268383
    Hejreskovvej 10A
    Kvistgaard, DK-3490
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register